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to change, associations with other criterion standards, and indicators
of Alzheimer’s disease [AD] severity) of a quality-of-life measure
(Quality of Life in Alzheimer’s Disease [QOL-AD]) and a health utility
measure (Health Utilities Index Mark 3 [HUI-3]) from two recently
completed clinical trials of a new drug for AD. Methods: Change from
baseline scores was calculated, and treatment effects were analyzed
using mixed models for repeated measures. Three separate models
were then estimated to examine the association between the quality-
of-life/utility end points and the clinical and other health outcome
end points measured during the trials, including cognition, function,
behavior, and dependence. Results: The performance of the two
measures differed. Subject-assessed QOL-AD was found to be weakly
associated with clinical measures of cognition, and with caregiver
reports of function, behavior, and dependence, and showed little
movement over time and did not appear to differ by baseline AD
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using proxy-assessed QOL-AD. Proxy-assessed HUI-3 scores were more
strongly associated with clinical measures of cognition, function,
behavior, and dependence than the subject- and proxy-assessed QOL-
AD scores. Larger proportionate changes over 78 weeks were observed
with HUI-3 scores and greater separation in HUI-3 scores by baseline
severity. Conclusions: Subject-assessed QOL-AD is less likely than
proxy-assessed QOL-AD to respond to changes in clinical measures
used to track progression in clinical trials of subjects with mild to
moderate AD. Proxy-assessed HUI-3 assessments were more in line
with other outcome assessments and could therefore be better outcome
measures to evaluate clinical progression in mild to moderate AD.
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Quality-of-life (QOL) assessment is increasingly important in the
regulatory assessment of new drugs [1,2]. Equally, utility is
important as part of health technology assessments surrounding
funding decisions [3]. There has been much debate about how
best to measure health-related QOL and utility in Alzheimer’s
disease (AD) because of challenges of changing cognitive per-
formance and patient insight over the course of a study and
concerns about bias among family caregivers who provide proxy
assessments [4]. There have been a number of reviews on QOL
assessment in AD [5,6]. The Quality of Life in Alzheimer’s Disease
(QOL-AD) is one of the most frequently used QOL measures in AD
and offers both patient-assessed and proxy-assessed options [7].The QOL-AD has been widely used in cross-sectional [8–15]
and longitudinal observation studies [16–18], in a clinical trial
examining long-term follow-up strategies for patients with AD
[19], and in a 6-month study examining the efﬁcacy of Ginko
Biloba [20]. These studies have already provided useful informa-
tion about determinants of QOL-AD scores assessed by the
patient and the proxy: in general, depression, anxiety, insight,
and use of antidementia treatment have been shown to be
associated with patient-assessed QOL-AD while proxy-assessed
QOL-AD is determined by many factors including patient
impaired function, neuropsychiatric symptoms, cognition,
dependency, and caregiver characteristics. On the basis of these
ﬁndings, researchers have argued that the patient and proxy
ratings should be considered complementary and not combinedociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 3 8 – 6 4 5 639in a composite score. A European consensus panel recommended
the QOL-AD as a measure of choice for evaluating psychosocial
interventions research in dementia care, having reviewed the
literature on a number of QOL outcome measures [21].
Recent long-term observational studies have shown that
larger mean changes might be expected in the proxy-assessed
QOL-AD than in the patient-assessed QOL-AD. In a 2-year follow-
up study, patient-assessed QOL-AD scores did not change sig-
niﬁcantly but proxy-assessed QOL-AD scores did change signiﬁ-
cantly [17]. In a 3-year follow-up observational study, there was a
signiﬁcant decline in mean scores for proxy-assessed QOL-AD at
12 and 36 months, but vast individual differences in QOL-AD
scores [16]. The authors noted that “the wide variation in changes
from baseline may affect the validity of using QoL measures as
efﬁcacy parameters because improvements in QoL cannot with
certainty be appraised as an effect of the intervention.”
Shearer et al. [22] reviewed the literature on the use of the Health
Utility Index Mark 3 (HUI-3) in AD and concluded that the “validity of
the HUI3 for caregiver reports was supported in two studies [23,24]
although the validity of the HUI3 for use in AD patients (i.e., patient
completed) has been queried due to poor correlations with patient
self-assessments of functional status” [23]. For self-completion by
patients with mild dementia and for proxy completion, the reli-
ability of the HUI-3, using test-retest reliability (intraclass correlation
coefﬁcients), has been reported to be 0.70 or more [23].
Two recently completed randomized clinical trials of bapineu-
zumab, despite failing to show signiﬁcant efﬁcacy on the primary
outcomes of cognition and function [25], provide a rich data set to
investigate the performance of the subject- and proxy-assessed
QOL-AD as well as the performance of the proxy-assessed HUI-3
as a measure of utility and its interrelationships with multiple
symptoms, including measures of cognition, function, behavior,
and dependence. The primary objective of Study ELN115727-301
and Study ELN115727-302 (hereafter referred to as Study 301 and
Study 302, respectively) was to demonstrate the safety and
efﬁcacy of multiple doses of intravenously administered bapineu-
zumab in patients with mild to moderate AD compared with
placebo (Study 301: NCT00667810 and Study 302: NCT00676143).
This article presents a comprehensive evaluation of the
performance of subject- and proxy-assessed QOL-AD and the
proxy-based HUI-3 based on pooled data from these two placebo-
controlled randomized clinical trials investigating the efﬁcacy of
bapineuzumab. These analyses could inform decisions about the
usefulness of QOL-AD and HUI-3 in future clinical trials in those
with mild to moderate AD. Moreover, the multitude of other
instruments and indicators of health status in this trial allows for
a better understanding of the determinants of QOL. This may
help other evaluations of interventions to improve both patient-
and proxy-assessed QOL in patients with mild to moderate AD.Methods
Study Design
Study 301 and Study 302 were multicenter, randomized, double-
blind, placebo-controlled, parallel-group outpatient studies in
male and female subjects aged 50 years to younger than 89 years
with mild to moderate AD (Study 301: ClinicalTrials.gov identiﬁer
NCT00667810 and Study 302: ClinicalTrials.gov identiﬁer
NCT00676143). Study 302 was conducted at 170 sites in the United
States from December 2007 through April 2012 and included
participants who were carriers of the apolipoprotein E (APOE) ε4
allele, a genetic risk factor for AD. Study 301 was conducted at 218
sites in the United States (195 sites), Canada (17), Germany (4), and
Austria (2) from December 2007 through June 2012 and included
participants who were noncarriers [26]. Bapineuzumab or placebowas administered via an intravenous infusion every 13 weeks for a
total of six infusions over the course of the 78-week study. Informed
consent was obtained from all participants, or, if not capable of
providing informed consent, from their legally acceptable represen-
tative. The studies were conducted according to the Declaration of
Helsinki and were approved by independent review boards.
Full inclusion and exclusion criteria are described elsewhere
(Study 301: NCT00667810 and Study 302: NCT00676143). Brieﬂy,
subjects were enrolled in the study if they were aged 50 years to
younger than 89; had a diagnosis of probable AD according to the
National Institute of Neurological and Communicative Disorders
and Stroke/Alzheimer’s Disease and Related Disorders Association
criteria and a screening visit brain magnetic resonance imaging
scan consistent with a diagnosis of AD; a Mini-Mental State
Examination (MMSE) score of 16 to 26 inclusive; a Rosen Modiﬁed
Hachinski Ischemic score [27] of 4 or less; and lived at home or
independently in a community dwelling and had a caregiver who
consented to participate in the study, could accompany the subject
on all clinic visits, and was a reliable informant in the opinion of
the investigator. Subjects were excluded if they had clinically
signiﬁcant neurological disease other than AD; a major psychiatric
disorder; history of stroke or seizures; a brain magnetic resonance
imaging scan indicative of signiﬁcant non-AD abnormality; or
history or evidence of any clinically signiﬁcant autoimmune
disease or chronic illness that was likely to result in deterioration
affecting the subject’s safety during the study.
The QOL-AD and HUI-3 [28] were administered at baseline,
week 26, week 52, and week 78. Both caregivers and patients
completed the QOL-AD, but only the caregivers completed the
self-administered proxy version of the HUI-3. The QOL-AD is a 13-
item questionnaire designed to provide both a subject report and
a caregiver report of the subject’s QOL. Points are assigned to
each item as follows: poor ¼ 1, fair ¼ 2, good ¼ 3, and excellent ¼
4. The total score is the sum of all the 13 items and the total range
of possible scores is 13 to 52 (higher scores indicate better QOL).
The proxy version of HUI-3 is a generic, preference-weighted,
health status assessment system completed by the caregiver. The
proxy version encompasses 16 questions (one additional item
than the self-reported version to identify the relationship of the
respondent) that are used to obtain data about patients so that
their health status can be described using HUI-3 health states,
and ultimately a preference-based utility score for their health.
Possible HUI-3 utility values can range from 0.36 (worse than
death) to 1 (perfect health), with 0 representing death.
At baseline, week 26, week 52, and week 78, cognitive function
was assessed using the Alzheimer’s Disease Assessment Scale-
Cognitive Subscale (AQDAS-COG; range 0–70) [29], functional ability
was assessed with the Disability Assessment for Dementia (DAD;
range 0%–100%) [30], and neuropsychiatric symptoms were
assessed with the Neuropsychiatric Inventory (NPI; range 0–144)
[31]. Patient dependence on others was assessed using the depend-
ence scale (DS; range 0–15) [32]. Global disability was assessed
using the Clinical Dementia Rating Scale-Sum of Boxes [33]. MMSE
(0–30) [34] assessments were also made at baseline and at weeks
19, 32, 45, 58, and 78. To estimate MMSE levels at weeks 26 and 52,
the mean of two assessments (19 and 32; 45 and 58) was calculated.Analysis
Level of Change Analysis Using Individual Study Data
For the individual studies, change from baseline scores was
calculated for the subject-assessed QOL-AD scores and the
proxy-assessed QOL-AD scores at week 78 and treatment effects
were analyzed using a restricted maximum likelihood–based
mixed model for repeated measures, similar to that used for
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statistics were prespeciﬁed for the analysis of HUI-3 utility scores
in the different treatment groups.
Analysis Using Pooled Data Set
Using the pooled data set from both studies, mean changes in the
QOL-AD and HUI-3 scores at week 78 were determined for three
subgroups of patients with the following baseline severity: very
mild (MMSE score Z 24), mild (MMSE score Z 21), and moderate
(MMSE score o 21).
Pearson correlations between the QOL-AD and utility meas-
ures and the other clinical measures were determined for each of
the four assessment times: baseline, week 26, week 52, and week
78. A priori, the strength of the correlation coefﬁcient to establish
concurrent validity between the QOL-AD and the other scales was
considered: 0 to 0.25 ¼ little if any correlation, 0.26 to 0.49 ¼ low
correlation, 0.50 to 0.69 ¼ moderate correlation, 0.70 to 0.89 ¼
high correlation, and 0.90 to 1.0 ¼ very high correlation. Moderate
correlation would be considered useful because this would mean
that the scales were associated, but not redundant.
Using restricted maximum likelihood–based mixed models for
repeated measures, three separate models were estimated: Model
1 examined the association between QOL/utility and the DS;
model 2 examined independent associations between AQDAS-
COG, DAD, and NPI and OQL/utility; and model 3 examined
independent associations between MMSE, DAD, and NPI and
QOL/utility. MMSE and AQDAS-COG were not included in the
same model because of concerns about multicollinearity. All
models also controlled for patient age, sex, and assessment time.Results
Demographic and Baseline Characteristics
Patients’ demographic and baseline characteristics for patients par-
ticipating in studies 301 and 302 and for the pooled data set are
presented in Table 1. In study 301, 493 and 621 patients received
placebo and bapineuzumab (0.5 and 1.0 mg/kg), respectively, while
432 and 658 patients received placebo and bapineuzumab (0.5 mg/kg),
respectively, in study 302. The two treatment groups were similar at
baseline with respect to patient age, sex, duration of AD, and severity
of AD asmeasured by the MMSE, AQDAS-COG, DAD, NPI, and DS [26].Table 1 – Patients’ demographic and baseline characteris
Characteristic Study 301
Placebo Bapineuzumab
(pooled)(N ¼ 493)
(N ¼ 621)
Sex, n (%)
Male 245 (49.7) 281 (45.2)
Female 248 (50.3) 340 (54.8)
Age (y) 71.9  10.10 73.1  9.35
Duration of AD (y) 3.1  2.32 3.1  2.43
MMSE score 21.2  3.21 21.2  3.31
AQDAS-COG 22.2  10.08 22.3  9.85
DAD 80.5  19.5 80.2  18.46
NPI 11.2  12.42 11.0  12.60
DS 4.6  2.23 4.6  2.29
Note. Values are mean  SD unless indicated otherwise.
AQDAS-COG, Alzheimer’s Disease Assessment Scale-Cognition; DAD, Dis
Mental State Examination; NPI, Neuropsychiatric Inventory.Changes in QOL-AD and HUI-3 Over Time
The QOL-AD subject and caregiver baseline scores and adjusted
least squares (LS) mean (standard error) change scores at week 78
are presented in Table 2. Change in subject-assessed QOL-AD was
small, with LS mean changes of 0.6 versus 0.2 and 0.3 versus
0.6 for placebo and bapineuzumab for studies 301 and 302,
respectively. No signiﬁcant differences across treatments were
observed. The average baseline scores for QOL-AD proxy were
consistently lower, by approximately 3 points, than the corre-
sponding subject-assessed QOL-AD scores. Change in caregiver
proxy–assessed QOL-AD was larger at week 78, with LS mean
changes of 2.3 versus 2.7 and 2.3 versus 2.6 for placebo and
bapineuzumab for study 301 and study 302, respectively. No
signiﬁcant differences across treatments were observed.
The HUI-3 baseline and unadjusted mean change in scores at
week 78 is presented in Table 3. No statistical testing of changes
was conducted because the study protocol had prespeciﬁed
descriptive statistics.
Changes in mean scores for placebo and bapineuzumab were
0.123 versus 0.123 and 0.123 versus 0.137 for studies 301
and 302, respectively. The proportionate change was consider-
ably larger than that observed for the QOL-AD. HUI-3 utility
values can range from 0.36 (worse than death) to 1.00 (perfect
health); hence, a decline of between 0.123 and 0.137 is a
proportionate change of between 9.0% and 10.0%. QOL-AD total
scores range from 13 (worse QOL) to 52 (better QOL); hence, a
decline of between 0.2 and 0.6 in the QOL-AD subject total
score is a proportionate change of between 0.05% and 1.5%. A
decline of 2.3 and 2.7 in the QOL-AD caregiver proxy total
score is a proportionate change of between 5.9% and 6.9%.Changes in QOL-AD and HUI-3 by Baseline Severity
Table 4 presents the mean baseline QOL-AD and HUI-3 scores for
patients in different subgroups based on their baseline MMSE
score, in addition to the mean change in scores at week 78.
Baseline subject-assessed QOL-AD varied little by severity level,
with an average score of 40.1 in subjects with very mild AD and
40.1 in subjects with moderate AD. Change scores were small but
tended to be larger in patients with moderate AD than in those
with very mild and mild AD.
At baseline, caregiver proxy–assessed QOL-AD tended to be
lower in subjects with moderate AD than in subjects with lesstics.
Study 302 Pooled 301 þ 302
Placebo Bapineuzumab
(0.5 mg/kg)
Total
(N ¼ 432)
(N ¼ 658)
(N ¼ 2204)
190 (44.0) 300 (45.6) 1016 (46.1)
242 (56.0) 358 (54.4) 1188 (53.9)
72.3  8.40 72.0  8.03 72.4  8.94
3.5  2.48 3.4  2.37 3.2  2.40
20.7  3.17 20.8  3.15 21.0  3.22
23.9  9.52 23.5  9.44 22.9  9.74
79.4  18.85 80.9  17.32 80.3  18.36
10.1  11.75 10.0  11.85 10.6  12.18
4.8  2.0 4.7  2.07 4.7  2.16
ability Assessment for Dementia; DS, dependence scale; MMSE, Mini-
Table 2 – Subject- and caregiver proxy–assessed QOL-AD total scores: Observed values and change from
baseline to week 78.
QOL-AD total score Study 301 Study 302
Placebo
(N ¼ 493)
Bapineuzumab
(pooled)*
Placebo
(N ¼ 432)
Bapineuzumab
(0.5 mg/kg)
(N ¼ 621) (N ¼ 658)
QOL-AD subject-assessed total score
Baseline, N 489 618 429 650
Baseline, mean  SD 39.7  5.64 39.4  5.43 41.0  5.05 40.8  5.21
Change from baseline at week 78, N 349 430 321 439
Change from baseline at week 78, mean (SE)† 0.6 (0.24) 0.2 (0.21) 0.3 (0.26) 0.6 (0.22)
Difference in means (95%) 0.4 (0.3, 1.0) 0.3 (0.9, 0.4)
P-value 0.257 0.406
QOL-AD caregiver proxy–total score
Baseline, N 493 621 431 657
Baseline, mean  SD 36.0 (5.93) 36.5 (5.92) 37.4 (5.56) 37.0 (5.67)
Change from baseline at week 78, N 365 446 334 457
Change from baseline at week 78, mean (SE)† 2.3 (0.26) 2.7 (0.24) 2.3 (0.26) 2.6 (0.22)
Difference in means (95%) 0.4 (1.1, 0.3) 0.3 (1.0, 0.4)
P-value 0.252 0.400
MMSE, Mini-Mental State Examination; QOL, quality of life; QOL-AD, Quality of Life in Alzheimer’s Disease; SE, standard error.
* Bapineuzumab 0.5 mg/kg and 1.0 mg/kg pooled.
† Mixed model for repeated measures with change from baseline as the response variable and the ﬁxed-effect model terms for treatment, visit
(scheduled week), treatment-by-visit interaction, baseline value, baseline value-by-visit interaction, MMSE total score stratum, cholinester-
ase inhibitor or memantine use stratum, APOE*E4 allele copy number stratum, and baseline age. Treatment differences (bapineuzumab
minus placebo) are estimated using least squares means with factor levels weighted according to overall baseline sample proportions.
A positive difference (bapineuzumab minus placebo) favors bapineuzumab. Total scores range from 13 (worse QOL) to 52 (better QOL);
a positive change from baseline indicates improved QOL.
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for the moderate group.
HUI-3 scores showed a wider separation than did the QOL-AD
scores across the severity subgroups, with a mean baseline level
of 0.543 for subjects with very mild AD and 0.409 for subjects with
moderate AD. Change scores showed the same trend, with
subjects with moderate AD having an average change score of
0.157 compared with 0.110 for subjects with very mild AD.Bivariate and Covariate-Adjusted Associations
Correlations between subject-assessed QOL-AD, proxy-assessed
QOL-AD, and HUI-3 and other clinical variables are presented in
Figure 1. Results of the mixed models are presented in Table 5.Table 3 – HUI-3 total score: Observed values and change
HUI-3 total score 301
Placebo Bapineuzumab (po
(N ¼ 493) (N ¼ 621)
Baseline
N 493 620
Mean  SD 0.452  0.2541 0.462  0.2469
Change from baseline week 78
N 365 448
Mean  SD 0.123  0.2611 0.123  0.2593
Note. The HUI-3 total score anchor points range from 0.00 (dead) to 1.00
utility.
HUI-3, Health Utility Index Mark 3.
* Bapineuzumab 0.5 mg/kg and 1.0 mg/kg pooled.Subject-assessed QOL-AD was highly correlated with caregiver
proxy–assessed QOL-AD. There were weak but signiﬁcant corre-
lations with clinical measures of cognition (AQDAS-COG and
MMSE), function (DAD), behavior (NPI), dependence (DS), and
global disability (Clinical Dementia Rating Scale-Sum of Boxes)
(Fig. 1A). The associations, indicated by beta coefﬁcients in
models 1 to 3 for subject-assessed QOL-AD, were relatively small
but statistically signiﬁcant for AQDAS-COG, DAD, NPI, and DS, but
not for MMSE, in agreement with the weak correlations observed
above (Table 5).
Proxy-assessed QOL-AD was weakly correlated with other
clinical measures. There were higher correlations with other
proxy-reported measures (DAD, NPI, DS, and Clinical Dementia
Rating) and lower correlations with clinician-reported measures
(MMSE and AQDAS-COG). There was a moderate correlation withs from baseline.
302
oled)* Placebo Bapineuzumab (0.5 mg/kg)
(N ¼ 432) (N ¼ 658)
431 657
0.477  0.2310 0.468  0.2487
333 457
0.123  0.2323 0.137  0.2477
(perfect health); a positive change from baseline indicates improved
Table 4 – QOL-AD and HUI-3 scores: Observed values and changes from baseline in severity subgroups.
QOL-AD and HUI-3 total score Very mild Mild Moderate Total
(MMSE score Z 24) (MMSE score Z 21) (MMSE score r 21)
QOL-AD subject
Total score, N 643 1261 1058 2319
Baseline, mean  SD 40.1  5.32 40.3  5.41 40.1  5.31 40.2  5.36
Change from baseline at week 78,
mean  SD
0.0  4.68 0.2  4.94 0.9  5.38 0.5 5.14
QOL-AD caregiver proxy
Total score, N 646 1268 1067 2335
Baseline, mean  SD 37.9  5.54 37.3  5.65 35.9  5.80 36.7  5.76
Change from baseline at week 78,
mean  SD
1.9  5.65 2.0  5.43 3.0  5.46 2.4 5.46
HUI-3
Total score, N 645 1267 1067 2334
Baseline, mean  SD 0.543  0.249 0.511  0.248 0.409  0.232 0.464  0.246
Change from baseline at week 78,
mean  SD
0.110  0.253 0.104  0.259 0.157  0.239 0.127  0.252
HUI-3, Health Utility Index Mark 3; MMSE, Mini-Mental State Examination; QOL-AD, Quality of Life in Alzheimer’s Disease.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 3 8 – 6 4 5642HUI-3 (Fig. 1B). The associations, indicated by beta coefﬁcients in
models 1 to 3, were larger than for the subject-assessed QOL-AD
and statistically signiﬁcant for MMSE, DAD, NPI, and DS but not
for AQDAS-COG (Table 5).
The proxy-assessed HUI-3 was moderately correlated with other
clinical measures. Unlike the subject-assessed and proxy-assessed
QOL-AD, there was a weak but signiﬁcant correlation associated
with age. The associations, as indicated by beta coefﬁcients, were
relatively large and statistically signiﬁcant (Table 5).Discussion
The lack of signiﬁcant treatment differences in subject- and
proxy-assessed QOL-AD changes at week 78 in study 301 and
study 302 is consistent with the lack of clinical efﬁcacy previously
reported [26]. The large sample size (2000þ patients), longitudinal
data (18 months), and data on a wide spectrum of clinical
measures, however, provided an opportunity to thoroughly
investigate the performance of the subject- and proxy-assessed
QOL-AD in addition to the proxy-assessed HUI-3.
Our results suggest that subject-assessed QOL-AD is less likely
than proxy- assessed QOL-AD to respond to changes in clinical
measures that are frequently used to assess disease progression
and efﬁcacy in clinical trials in those with mild to moderate AD.
Subject-assessed QOL-AD was found to be weakly associated
with clinical measures of cognition (MMSE and AQDAS-COG),
and with caregiver reports of function (DAD), behavior (NPI), and
dependence (DS), and, in our sample, showed little movement
over time and did not appear to differ by baseline AD severity.
This is consistent with other research indicating that, in general,
depression, insight, and use of antidementia treatment have
been shown to be associated with patient-assessed QOL-AD and
not other clinical measures [35,36].
Our observations that proxy-assessed QOL-AD scores were
consistently lower than subject-assessed scores and level of
decline in QOL-AD greater using proxy-assessed QOL-AD are
consistent with the ﬁndings of others [17]. This was further
supported by the larger changes observed at week 78 in the
individual 301 and 302 studies. It is important to note, however,
that although such changes were greater than for subject-
assessed QOL-AD, they were relatively small. For example, the
LS mean changes after 78 weeks did not exceed 3 points, a
change that is frequently used to deﬁne the “minimal clinicallyimportant difference,” for the QOL-AD proxy [19]. Our analysis of
changes across subjects with different baseline severity did show
that patients with moderate AD had a mean change of 3.0 at
week 78. This suggests that the rate of change in proxy-assessed
QOL-AD may be sufﬁcient to detect minimal clinically important
differences in QOL in 18-month studies in subjects with moderate
AD. But the smaller changes observed in patients with milder AD
at week 78 suggest that it may be difﬁcult to detect differences in
such patients over an 18-month period on the basis of a
deﬁnition of a 3-point minimal important difference. Despite
some overlap between proxy and subject data, the patients
consistently reported less change over this time period.
Our results further suggest that proxy-assessed HUI-3 scores
are more strongly associated with clinical measures of cognition,
function, behavior, and dependence than subject- and proxy-
assessed QOL-AD scores. Consistent with this ﬁnding, we
observed larger proportionate changes over 78 weeks with HUI-
3 and greater separation in HUI-3 scores by baseline severity.
HUI-3 domains include eight health dimensions: vision, hearing,
speech, ambulation, dexterity, emotion, cognition, and pain. The
inclusion of the cognition domain has been used to support the
inclusion of HUI-3 in AD clinical trials over an alternative utility
measure, the EuroQol ﬁve-dimensional questionnaire, which
lacks a cognition dimension. Based on these ﬁndings, the
proxy-assessed HUI-3 would appear to be a useful measure for
inclusion in clinical trials investigating disease-modifying treat-
ments in those with mild to moderate AD. The mixed-models
analysis shows that HUI-3 utility scores are independently
associated with measures of cognition (MMSE and AQDAS-COG),
function (DAD), and behavior (NPI) and beta coefﬁcients provide
quantitative estimates for changes in HUI-3 that might be
expected per unit changes in these clinical measures. As noted,
however, HUI-3 includes (in addition to cognition and emotion)
items related to general age-related disability or to progression in
other chronic illnesses; thus, changes in HUI-3 that were
observed in our sample over the 78-week follow-up period may
be inﬂated because of decline in vision, hearing, or other physical
changes that affect performance on cognitive and clinical meas-
ures but that might not respond to treatment of dementia.
Strengths and Limitations
By pooling data from two large randomized clinical trials, this
study provided a robust study design for the comparison of
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Fig. 1 – (A) Correlations between subject-assessed QOL-AD
and other end points at speciﬁc time points in the trials. (B)
Correlations between caregiver proxy–assessed QOL-AD and
other end points at speciﬁc time points in the trials. (C)
Correlations between proxy-assessed HUI-3 and other end
points at speciﬁc time points in the trials. Notes. All
correlations with the exception of those marked with an
asterisk are statistically signiﬁcant (P o 0.05). Sign of
correlations: age (þ); sex (); AQDAS-COG (); MMSE (þ);
DAD (þ); NPI (); DS (); CDR (); QOL-AD pt (þ); QOL-AD cg
(þ). AQDAS-COG, Alzheimer’s Disease Assessment Scale-
Cognition; CDR, Clinical Dementia Rating; DAD, Disability
Assessment for Dementia; DS, dependence scale; HUI-3,
Health Utilities Index Mark 3; MMSE, Mini-Mental State
Examination; NPI, Neuropsychiatric Inventory; QOL-AD cg,
Quality of Life in Alzheimer’s Disease-caregiver assessed;
QOL-AD pt, Quality of Life in Alzheimer’s Disease-patient-
assessed.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 3 8 – 6 4 5 643placebo and bapineuzumab and a large data set to investigate the
performance of QOL-AD and HUI in patients with different AD
severity. The broad spectrum of clinical measures collected
allowed a comprehensive investigation of associations. Measuresof insight and depression, domains that have been shown to be
inﬂuential in determining subject-assessed QOL-AD, however,
were not collected, and many of the other clinical end points
were based on caregiver proxy report rather than objective
observation.
Because bapineuzumab treatment was not effective, the study
design did not allow us to investigate QOL and utility changes in
a scenario in which the clinical measures improve over time, and
so any conclusions about responsiveness cannot be applied to
such a scenario. Our conclusions apply only to those situations in
which disease-modifying treatments are under investigation and
the background illness is deteriorating.
Our analysis of subject-assessed QOL-AD clearly identiﬁed
weak associations with AQDAS-COG, MMSE, DAD, NPI, and DS
but did not identify what factors do play a role, which is a
limitation of the research. Our analysis of HUI-3 indicates that it
holds promise as an outcome of health utilities, but its inclusion
of items speciﬁc to age-related disability and progression of other
common chronic illnesses may be problematic in investigations
of dementia-speciﬁc QOL.
It should be noted that the results observed are applicable to a
clinical trial population meeting similar eligibility criteria. The
exclusion of patients with other neurologic or major psychiatric
disease limits the generalizability of the study results to the total
AD population; hence, we need to be cautious with our inter-
pretations. In some respects, however, this is one of the most
extensive cohorts ever rigorously studied and observed for this
period.Further Research
Further work is required to understand QOL and the relationship
between cognitive, functional, behavioral, and caregiver factors
that inﬂuence QOL in AD. Based on current ﬁndings, the most
effective treatment approaches in mild to moderate AD may need
to be multifactorial, including treatment not only speciﬁcally
targeting cognitive change but also recognizing and treating
mood, behavioral, and caregiver characteristics that also inﬂu-
ence QOL. Both the QOL-AD and HUI-3 provide information that
may be helpful in developing and evaluating such interventions,
but additional work is needed to reﬁne and strengthen the
measurement of QOL in AD.Conclusions
In this clinical trial population it appears that HUI-3 has prefer-
ential psychometric properties. Subject-assessed QOL-AD is less
likely than proxy-assessed QOL-AD to respond to changes in
clinical measures used to track the progression of subjects with
mild to moderate AD in clinical trials. The proxy-assessed HUI-3
assessment is likely to respond to changes in these clinical
progression measures in mild to moderate AD, but the changes
may not be speciﬁc to AD-related factors. More work is required
to understand what drives subject-assessed QOL and how to best
evaluate time- and treatment-related QOL changes in individuals
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Table 5 – Associations (regression coefﬁcients) between clinical variables and QOL-AD (patient- and proxy-
assessed) and HUI-3 using mixed-effects models for repeated measures.
Independent
variable
Dependent variables
Subject-assessed QOL-AD Proxy-assessed QOL-AD HUI-3
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
AQDAS-COG 0.00977* 0.00192 0.00306†
MMSE 0.02044 0.00951‡ 0.00745†
DAD 0.01982† 0.0253† 0.08627† 0.08329† 0.00393† 0.00394†
NPI 0.04906† 0.04909† 0.14852† 0.1477† 0.00531† 0.0054†
DS 0.22908† 1.02338† 0.05931†
Intercept 38.23† 37.70† 39.75† 31.17† 31.34† 40.57† 0.58† 0.36† 0.97†
No. of
observations
7706 7586 8005 7819 7694 8139 7818 7693 8136
Notes. All models controlled for age, sex, and assessment week; for patient-assessed QOL-AD, week was signiﬁcant for models 1 and 3 (P o
0.05); for proxy-assessed QOL-AD, week was signiﬁcant for all models (Po 0.0001); for HUI-3, age and week were signiﬁcant for all models (Po
0.0001) and sex for models 2 and 3.
AQDAS-COG, Alzheimer’s Disease Assessment Scale-Cognition; DAD, Disability Assessment for Dementia; DS, dependence scale; HUI-3, Health
Utilities Index Mark 3; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory; QOL-AD, Quality of Life in Alzheimer’s Disease.
* P ¼ 0.0005.
† P o 0.0001.
‡ P ¼ 0.005.
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